Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2022-11-16

FDA Approved: MESALAMINE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for mesalamine from Teva Pharmaceuticals USA to update the product labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Mesalamine (Mesalamine)

Snippet

SUPPL AP for MESALAMINE (MESALAMINE)